Morgan Steve, Kennedy Jae
School of Population and Public Health, University of British Columbia, Canada.
Issue Brief (Commonw Fund). 2010 Jun;89:1-12.
This issue brief contrasts prescription drug access, affordability, and costs in the United States with six other high-income countries, drawing from Commonwealth Fund survey data of patient experiences as well as international spending and pricing data. The analysis reveals that Americans, particularly the relatively young and healthy, are more likely to use prescription drugs than are residents of Australia, Canada, Germany, the Netherlands, New Zealand, and the United Kingdom, but they also experience more financial barriers in accessing medications and spend more out-of-pocket for prescriptions. In the U.S., there are also larger income-related inequities in pharmaceutical use. Despite access barriers and disparities, spending per person in the U.S. is far higher, likely the result of paying higher prices for similar medications and using a more expensive mix of drugs. The authors say that value-based benefit designs, reference pricing, and group purchasing could reduce financial barriers and keep down pharmaceutical spending.
本问题简报对比了美国与其他六个高收入国家的处方药获取、可负担性和成本情况,数据来源于英联邦基金关于患者体验的调查数据以及国际支出和定价数据。分析显示,美国人,尤其是相对年轻且健康的人群,比澳大利亚、加拿大、德国、荷兰、新西兰和英国的居民更有可能使用处方药,但他们在获取药物时也面临更多经济障碍,并且在处方药上的自付费用更高。在美国,药物使用方面与收入相关的不平等现象也更为严重。尽管存在获取障碍和差异,但美国的人均支出要高得多,这可能是因为对类似药物支付了更高价格,以及使用了更昂贵的药物组合。作者表示,基于价值的福利设计、参考定价和团购可以减少经济障碍并控制药品支出。